Cytokines released by cancer-associated fibroblasts (CAF) counteract the anti-tumoral effect of HER2/PI3K targeting via the upregulation of the MAPK pathway, as indicated by the ability of the MEK inhibitor-based combination to induce tumor shrinkage [17,30]. The gene discussed is ERBB2; the disease is neoplasm.